EMERAM's portfolio company Meona acquires Dr. Heni SOFTWARE, expanding its product portfolio

Nachricht vom 15.03.201915.03.2019 (www.4investors.de) -

DGAP-Media / 15.03.2019 / 10:00

EMERAM's portfolio company Meona acquires Dr. Heni SOFTWARE, expanding its product portfolio

Munich, 15 March 2019 - Meona Group ("Meona"), a portfolio company of private equity firm EMERAM Capital Partners ("EMERAM") and an innovation leader in the field of clinical software, acquires Dr. Heni SOFTWARE GmbH & Co. KG ("Dr. Heni SOFTWARE"), a leading provider of high-performance software products which support pharmacists in the preparation, prescription and billing of cytostatic solutions.

With its software, Meona offers a forward-thinking solution for efficient patient care and patient management in hospitals and other facilities. Through the combination with the Belgian company E.care bvba, which develops software to support hospital treatment processes, Meona had already expanded its product range to include the product E.care ED, a process management control solution with intuitive treatment documentation for emergency rooms, in 2017. With the acquisition of Dr. Heni SOFTWARE, which was founded in 1998 by the clinical pharmacist Dr. Josef Heni, Meona once again significantly strengthens its product range and opens up new customer potential.

The two IT solutions Dr. Heni SOFTWARE offers, ZENZY (a program for organizing the production of cytostatic drugs) and the drug tax A-Taxe, are particularly used by hospital and public pharmacies.

Dr. Josef Heni, founder and owner of Dr. Heni SOFTWARE, said: "I am very happy to have found an ideal partner in Meona. I have known Meona's management team for a very long time and I know that with this team our products, ZENZY and A-Taxe, can be successfully further developed."

PD Dr. med. Tobias Schäfer, Joint Managing Director and CEO of Meona, commented: "Over many years, Dr. Heni has created efficient solutions for hospital pharmacies that are geared toward the needs of the market. We are very pleased to be able to complete the medication workflow with the integration of his solution and to offer the organization of the complex production of cytostatic drugs from a single source."

Dr. med. Matthias Wuttke, Joint Managing Director and CTO of Meona, added: "We see enormous potential to migrate our existing solutions to a modern IT platform and thus enable customers to make a smooth transition to state-of-the-art, high-performance technologies."

Fabian Furtmeier, Associate Partner at EMERAM, stressed: "With the acquisition of Dr. Heni SOFTWARE, we continue our Buy & Build strategy for Meona and boost Meona's position as one of the digital innovation leaders in the field of clinical software."

Since the end of 2017, Meona has been a portfolio company of EMERAM, an independent private equity firm for medium-sized companies in German-speaking countries. EMERAM is a long-term business development partner and supports the company with the consistent implementation of its growth strategy.

The parties have agreed not to disclose any financial details of the transaction. Dr. Josef Heni was advised by Dr. Heni und Partner Steuerberater Rechtsanwälte PartGmbB, Meona by FGvW (Freiburg) under the leadership of Dr. Hendrik Thies. Tax advice was provided by Boris Melzer from Melzer und Kollegen.


Meona GmbH was founded in Freiburg in 2008 by PD Dr. Tobias Schäfer and Dr. Matthias Wuttke. Together with doctors, nurses, pharmacists and other healthcare professionals they developed the Meona software, which meets the requirements of modern day-to-day hospital life. Meona makes an important contribution to the improvement of quality in the healthcare sector. The software provides more safety and time for patients, offers seamless, entirely digital processes, and facilitates cost-efficient treatment. Since the end of 2017, Meona has been a portfolio company of the private equity firm EMERAM, which has since supported the company in the consistent implementation of its growth strategy. Further information is available at www.meona.de


Dr. Heni SOFTWARE GmbH & Co. KG was founded in 1998 by the clinical pharmacist Dr. Josef Heni and supports pharmacies in the production and billing of cytostatics and other medicines with its software products ZENZY and A-Taxe. Cytostatic drugs are natural or synthetic substances that inhibit cell growth or cell division. Further information is available at www.heni-software.de


EMERAM is an independent private equity firm for mid-cap companies in the German-speaking area. Funds advised by EMERAM Capital Partners provide capital to drive the development of companies, drawing upon a fund volume of EUR 350m. Its team of experienced investment professionals currently oversees seven portfolio companies: Boards & More, Matrix42, diva-e Digital Value Enterprise, Xovis, Drahtzug Stein Group, frostkrone Tiefkühlkost and Meona Group.

EMERAM regards itself as a long-term business development partner for companies in five industry sectors: consumer goods, retail, industrial goods, business services and healthcare. The six founding partners combine in-depth market knowledge with operational experience in these sectors. Together, the team has successfully closed over 35 transactions and supported the development of portfolio companies by serving on over 40 advisory boards and supervisory boards. EMERAM Capital Partners was founded as an independent partnership in Munich in 2012.

Press contact EMERAM Capital Partners

Alwin Binder

Kekst CNC

Tel.: +49 89 599 458 178


Press contact Meona Group

Andrea Jelich

Meona GmbH

Tel.: +49 761 292899-0


End of Media Release
Issuer: EMERAM Capital Partners GmbH
Key word(s): Finance
15.03.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

787939  15.03.2019 

Aktuelle Nachrichten aus der 4investors-Redaktion

22.03.2019 - Software AG kündigt höhere Dividende an
22.03.2019 - cyan: „Bestätigen unsere Prognose für 2019”
22.03.2019 - Baader Bank will „schrittweise Profitabilität zurückgewinnen”
22.03.2019 - Ströer hebt die Dividende an
22.03.2019 - Wirecard: Ja dann macht es doch endlich! - Kommentar
22.03.2019 - Encavis hebt die Dividende an - „weiterhin voll im Plan”
22.03.2019 - Pyrolyx: Neue Aktien aus Wandlungen
22.03.2019 - Hapag-Lloyd erwartet für 2019 operatives Gewinnplus
22.03.2019 - SAF-Holland hält Dividende konstant - Bilanz vorgelegt
22.03.2019 - MS Industrie AG verkauft Teile des Daimler-Zuliefergeschäfts


22.03.2019 - Steinhoff Aktie: Das sind sehr interessante Beobachtungen!
22.03.2019 - Commerzbank Aktie hält wichtige Marke - Trendwende perfekt?
21.03.2019 - Wirecard Aktie: Achtung, neue Verkaufssignale!
21.03.2019 - Wirecard Aktie: Kommt der große Einbruch doch noch?
21.03.2019 - Wirecard Aktie: Platzt die nächste Bombe?
21.03.2019 - Bayer Aktie: Es kam, wie es kommen musste…
20.03.2019 - Bayer Aktie: Der Monsanto-Crash als Kaufgelegenheit?
20.03.2019 - Wirecard Aktie: Das sieht nicht gut aus!
20.03.2019 - Evotec Aktie: Jetzt! Endlich! Oder doch nicht?
20.03.2019 - Paragon Aktie: Die Luft wird verdammt dünn!


22.03.2019 - E.On und RWE: Kaufempfehlungen für die Aktien
22.03.2019 - DEAG Aktie: Kaufempfehlung bestätigt
22.03.2019 - Biofrontera Aktie: Starkes Aufwärtspotenzial
22.03.2019 - Scherzer Aktie: Experten wollen Modell bald überarbeiten
22.03.2019 - Geely Aktie: Geht hier was?
21.03.2019 - Bayer Aktie: Herausfordernde Zeiten
21.03.2019 - mVISE: Neues Kursziel für die Aktie
21.03.2019 - Fuchs Petrolub: Kaum noch Aufwärtspotenzial
21.03.2019 - BMW: Marge in der Kritik
21.03.2019 - Deutsche Post: Konkurrenz ermöglicht Veränderung


22.03.2019 - Steiler Bund & fallende Renditen: „Japanische Verhältnisse“ in Europa - Donner & Reuschel Kolumne
22.03.2019 - Weltwassertag: Investment in eine knappe Ressource - AXA IM Kolumne
22.03.2019 - DAX: Korrektur weitet sich aus - UBS Kolumne
22.03.2019 - Gold: Erholung in Form einer bearishen Flagge - UBS Kolumne
22.03.2019 - Börse in Südkorea erholt sich nach schwächerem Jahresstart - Commerzbank Kolumne
22.03.2019 - DAX: Brexit, Brexit, Brexit - „Kaugummi“ zieht sich - Donner & Reuschel Kolumne
21.03.2019 - USA: Fed setzt Zinspause fort bis sich der konjunkturelle Nebel gelichtet hat - Nord LB Kolumne
21.03.2019 - Fed: Zinserhöhungen sind 2019 vom Tisch - VP Bank Kolumne
21.03.2019 - Commerzbank Aktie: Pullback oder Trendwende? - UBS Kolumne
21.03.2019 - DAX: Aufwärtstrend bekommt Gegenwind - UBS Kolumne

All Right Reserved by minimalthemes - ©2018 Stoffels & Barck GbR